LivaNova PLC (NASDAQ:LIVN) Shares Sold by Sei Investments Co.

Sei Investments Co. reduced its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 41.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 52,675 shares of the company’s stock after selling 38,016 shares during the quarter. Sei Investments Co. owned 0.10% of LivaNova worth $2,439,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Central Pacific Bank Trust Division increased its stake in shares of LivaNova by 21.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after purchasing an additional 720 shares in the last quarter. Vestcor Inc purchased a new position in LivaNova during the fourth quarter worth $204,000. Captrust Financial Advisors acquired a new position in shares of LivaNova in the third quarter worth $217,000. Inceptionr LLC purchased a new stake in shares of LivaNova in the fourth quarter valued at $217,000. Finally, Sanctuary Advisors LLC acquired a new stake in shares of LivaNova during the third quarter valued at $219,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Stock Down 4.1 %

LIVN opened at $35.95 on Friday. LivaNova PLC has a 1 year low of $35.24 and a 1 year high of $64.48. The firm has a 50 day moving average price of $43.47 and a 200 day moving average price of $48.12. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The company has a market cap of $1.95 billion, a PE ratio of 85.60 and a beta of 0.90.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Barclays reduced their price target on LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research note on Friday, March 7th. Mizuho decreased their price target on LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. StockNews.com raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 25th. Needham & Company LLC reiterated a “buy” rating and set a $64.00 price objective on shares of LivaNova in a report on Monday, March 17th. Finally, The Goldman Sachs Group lowered their target price on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a report on Monday, March 3rd. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $61.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.